Deuber H J
III. Medizinischen Klinik, Klinikum Bamberg, BRD.
Wien Med Wochenschr. 1990 Aug 31;140(16):417-21.
With this study including 9 patients with angiographically proven coronary heart disease it could be shown that a monotherapy with nifedipine in the galenic preparation as Adalat SL (Bayer AG, Leverkusen, FRG) is efficient in reducing myocardiac ischemia and concomitantly raising working capacity during bicycle ergometry as well after first time application of this drug as after continuous therapy with 1 tablet twice daily during 4 weeks. This findings are true both at normal environmental conditions (1000 ft above sea level) and at conditions of altitude induced hypoxia (9000 ft above sea level), simulated in a hypobaric chamber. There was no development of drug tolerance during continuous therapy with 1 tablet of Adalat SL twice a day. Out of these findings the conclusion can be drawn that in patients with coronary heart disease receiving protective therapy with Adalat SL there is no remarkably higher risk of episodes of angina pectoris or even myocardiac infarction at altitudes up to 9000 ft above sea level than is to be expected during daily life.
本研究纳入了9例经血管造影证实患有冠心病的患者，结果表明，使用拜耳公司（德国勒沃库森）生产的硝苯地平速释片（Adalat SL）进行单一疗法，在首次用药后以及每日两次、每次一片、连续治疗4周后，均能有效减轻心肌缺血，并在自行车测力计运动期间提高工作能力。这一结果在正常环境条件下（海拔1000英尺）以及在低压舱模拟的高原缺氧条件下（海拔9000英尺）均成立。每日两次、每次一片服用Adalat SL进行连续治疗期间，未出现药物耐受性。基于这些发现，可以得出结论：在接受Adalat SL进行保护性治疗的冠心病患者中，在海拔高达9000英尺的地区，心绞痛发作甚至心肌梗死的风险并不比日常生活中预期的显著更高。
